BriaCell Therapeutics Corp. disclosed BriaPro Therapeutics Corp.'s unaudited condensed interim financial statements for the six months ended January 31, 2026, showing increased operating losses and minimal cash, furnished under Item 7.01 as Regulation FD disclosure.
Key takeaways
BriaPro reported operating loss of $497,943 for six months ended January 31, 2026 vs. $210,035 prior year.
Comprehensive loss of $472,231 for the period, with basic and diluted EPS of $(0.011).
Cash and equivalents remained at $1, with total assets of $176,890 and shareholders' deficit of $1,618,141.
Due to related parties increased to $1,606,112 from $1,121,053 at July 31, 2025.
On February 18, 2026, entered purchase agreement to acquire BriaCell's sCD80 license, closed March 30, 2026.
Jamieson Bondarenko appointed BriaPro board Chairman upon sCD80 transaction closing.